Astera Labs gets BMO Outperform rating, $375 target price
ALAB•BMO initiated coverage of Astera Labs with an Outperform rating and a $375 target price.
Related News
TIC Solutions Q3 net loss narrows 20% to $11.11 million; revenue rises 35% to $639.62 million
TIC•
1stDibs Q3 2026 net loss narrows 64% to $1.25 million
DIBS•
Evogene publishes update to financial calendar
EVGN•
Alnylam Pharmaceuticals target price raised to $292 from $290
ALNY•
Viatris Q3 adjusted EPS beats estimates; hikes forecast
VTRS•